

What is claimed is:

1. A method for treating unwanted neovascularity in a subject, comprising;
 - (a) administering an effective amount of an anti-angiogenic agent to the subject;
 - (b) administering an effective amount of a photosensitive agent to the subject; and
 - (c) irradiating the unwanted neovascularity with light having a wavelength absorbable by the photosensitive agent.

1 102
Article Anti-angiogenic activity of selected
all other W3,
Article 3
(date UK?)

2. The method of claim 1, wherein the anti-angiogenic agent is administered between about 0 and about 4 weeks before the administration of the photosensitive agent.

Article 3

3. The method of claim 1, wherein the anti-angiogenic agent and the photosensitive agent are administered simultaneously.

4. The method of claim 1, wherein the anti-angiogenic agent is administered between about 0 and about 4 weeks after the administration of the photosensitive agent.

Article 1

5. The method of claim 1, wherein the anti-angiogenic agent is administered between about 0 and about 4 weeks before the administration of the photosensitive agent and between about 0 and about 4 weeks after the administration of the photosensitive agent.

6271233

6. The method of claim 1, wherein the anti-angiogenic agent is selected from the group consisting of inhibitors of protein kinase C, antagonists of growth hormone, antagonists of IGF-1, antagonists of vascular endothelial growth factor, inhibitors of cyclooxygenase II, antagonists of angiotensin II, antagonists of NF-kappa B, and phospholipase A2 antagonists.

Article 1

7. The method of claim 6, wherein the anti-angiogenic agent is selected from the group consisting of inhibitors of protein kinase C and antagonists of vascular endothelial growth factor.

Article 2

✓ 8. The method of claim 7, wherein the anti-angiogenic agent is an inhibitor of protein kinase C.

Article 1

✓ 9. The method of claim 7, wherein the anti-angiogenic agent is selected from the group consisting of N-benzoyl-staurosporine, CGP 79787, and octreotide.

6214819

10. The method of claim 9, wherein the anti-angiogenic agent is N-benzoyl-staurosporine.

5770418
5214036
5095039

11. The method of claim 1, wherein the photosensitive agent is selected from the group consisting of a porphyrin and a purpurin.

12. The method of claim 11, wherein the photosensitive agent is benzoporphyrin derivative monacid ring A.

13. The method of claim 2, wherein multiple administrations of anti-angiogenic agent are performed prior to the administration of the photosensitive agent.

Article 3

14. The method of claim 4, wherein multiple administrations of anti-angiogenic agent are performed after the administration of the photosensitive agent.

Article 1

15. The method of claim 5, wherein multiple administrations of anti-angiogenic agent are performed prior to the administration of the photosensitive agent and wherein multiple administrations of anti-angiogenic agent are performed after the administration of the photosensitive agent.

16. A kit comprising at least one anti-angiogenic agent and at least one photosensitive agent.

17. The kit of claim 17, wherein the photosensitive agent is benzoporphyrin derivative monoacid ring A.

✓ 18. The method of claim 1, wherein the subject is suffering from choroidal neovascularization.

Article 3

✓ 19. The method of claim 1, wherein the subject is suffering from retinal neovascularization.

Article 3

- what is it for Article 3?
- Is Article 3 going to use?